

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

(Convertible Bonds Code: 40546)

REDEMPTION OF CONVERTIBLE BONDS PURSUANT TO EXERCISE OF PUT OPTION BY BONDHOLDERS

References are made to (i) the announcements of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) dated January 8, 2021, January 22, 2021, January 24, 2021 and January 25, 2021 in relation to, among others, the issue of Zero Coupon Convertible Bonds due 2026 (the “**Convertible Bonds**”) (collectively, the “**CB Announcements**”); and (ii) the monthly return of the Company dated January 5, 2023 in relation to repurchase of certain Convertible Bonds. Unless otherwise defined, the terms adopted in this announcement shall have the same meaning as those defined in the CB Announcements.

REDEMPTION OF CONVERTIBLE BONDS PURSUANT TO EXERCISE OF PUT OPTION BY BONDHOLDERS

As disclosed in the CB Announcements, pursuant to the terms and conditions of the Convertible Bonds, the holder(s) of the Convertible Bonds have the right at such holder’s option, to require the Company to redeem all or some only of the Bonds of such holder on January 22, 2024 (the “**Optional Put Date**”). To exercise such right, the Bondholder must complete, sign and deposit with any paying agent a duly completed and signed notice of redemption (“**Optional Put Exercise Notice**”) together with the certificate evidencing the Bonds to be redeemed not earlier than 60 days and not later than 30 days prior to the Optional Put Date.

As of the date of this announcement, the Company had received Optional Put Exercise Notices to redeem the outstanding Convertible Bonds in the aggregate principal amount of US\$590,622,000 (the “**Put Bonds**”) pursuant to the terms and conditions of the Convertible Bonds, representing approximately 99.10% in principal amount of the Convertible Bonds outstanding as at that date. Accordingly, the Company is required to redeem such Put Bonds at their principal amount on January 22, 2024.

The above-mentioned redemption will be satisfied by the internal sources of the Company. The Company considers that there will be no material impact on the financial position of the Company as a result of the above-mentioned redemption of the Convertible Bonds.

Following the redemption and cancellation of the Put Bonds, the Convertible Bonds in the principal amount of US\$5,378,000 will remain outstanding. The maximum number of Shares to be issued by the Company upon full conversion of the outstanding Convertible Bonds will be 702,765 Shares (assuming the conversion price per Conversion Share is HK\$59.33 and based on the fixed exchange rate of HK\$7.7529 = US\$1.00), representing approximately 0.012% of the Shares in issue as at the date of this announcement.

To the best of the knowledge, information and belief of the directors of the Company, having made all reasonable enquiries, the holder of the outstanding Convertible Bonds and its ultimate beneficial owner(s) are not connected persons of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, January 22, 2024

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.